Manager TitleAgeSince
President 63 2010-05-26
Director TitleAgeSince
Director/Board Member 63 2010-03-25
Director/Board Member 85 2011-05-31
Director/Board Member 79 2013-05-08
Change 5-day change 1-year change 3-year change Capi.($)
+0.03%+0.40% - - 0
+0.47%+2.27%+50.78%+70.84% 55.01B
+2.83%+0.48%+28.18%+82.59% 54.24B
+0.54%+1.22%-16.62%-13.47% 23.38B
-0.97%-3.30%-1.79%+383.00% 22.57B
+0.15%+1.39%+17.20%-9.05% 20.19B
-2.15%-2.30%+27.27%-31.03% 17.86B
-0.32%-3.75%+26.23%+536.72% 15.5B
-2.09%+0.64%+49.78%+178.74% 14.2B
-3.14%-8.47%+165.37%+292.18% 14.2B
Average -0.45%-0.56%+38.49%+165.61% 26.35B
Weighted average by Cap. +0.28%-0.11%+34.53%+130.62%
Logo TESARO Inc
TESARO, Inc. is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform. Rolapitant is a potent and long-acting neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting. Niraparib is an orally active and potent poly (adenosine diphosphate (ADP)-ribose) polymerase inhibitor. It has various ongoing clinical trials evaluating niraparib for the treatment of ovarian or breast cancers. It has initiated a Phase I, dose escalation study for its first immuno-oncology antibody, TSR-042, which targets Programmed cell death protein 1. It has commenced pre-clinical research for its antibody candidate targeting Lymphocyte-activation gene-3 andTSR-033. It has commenced a Phase I clinical trial of TSR-042.
Employees
-